Stay updated on Atrasentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Atrasentan in IgA Nephropathy Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0; Removed: Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4.SummaryDifference0.1%

- Check21 days agoChange Detected- Revision updated from v3.3.3 to v3.3.4 in the page header. This is a metadata change and does not modify the study details, eligibility criteria, or locations.SummaryDifference0.0%

- Check50 days agoChange DetectedThe study Locations list was updated to add new sites across the U.S., Argentina, Australia, Italy, China, India, Spain, and other regions, and several previously listed locations were removed.SummaryDifference2%

- Check71 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page, with no changes to the study details or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check78 days agoChange DetectedMinor metadata updates to the PubMed publications attribution and revision label in the study details (v3.3.1), replacing the previous PubMed attribution and revision (v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check85 days agoChange DetectedDeleted the government funding/operating status notice from the page, removing a generic informational banner. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Atrasentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atrasentan in IgA Nephropathy Clinical Trial page.